stockrow
Saturday 7 November 2026
Export BSEM’s income statement to Excel — free account
BioStem Technologies, Inc.
BSEM Healthcare Biotechnology
- Revenue
- −28.0%
- EPS
- −86,766.7%
Quarter to June 2026, against a year earlier
1.13
0.09
+8.65%
Follow BSEM
Alert me
BioStem Technologies, Inc. (BSEM) P/E ratio
BioStem Technologies, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 26.6× (November 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 6.9× | (55.67%) |
| FY2023 | 15.5× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 3.7× | (52.79%) |
| 8 more quarters | Free account |
Against its own ten years
Low 0.0×
High 26.6×
Ten-year median
3.9×
Current reading's percentile
36
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ATOS Atossa Therapeutics, Inc. compare | n/m |
| ACTU Actuate Therapeutics, Inc. compare | n/m |
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR compare | n/m |
| MCRB Seres Therapeutics, Inc. compare | n/m |
| ESLA Estrella Immunopharma, Inc. compare | n/m |
| KTTA Pasithea Therapeutics Corp. compare | n/m |
| COCP Cocrystal Pharma, Inc. compare | n/m |
| BSEM BioStem Technologies, Inc. | n/m |
| IMMP Prima BioMed Ltd compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)